Palisade Bio (PALI) Expected to Announce Earnings on Tuesday

Palisade Bio (NASDAQ:PALI) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Palisade Bio to post earnings of ($2.39) per share for the quarter.

Palisade Bio Trading Down 15.0 %

PALI stock opened at $0.85 on Tuesday. The firm has a 50 day moving average of $1.24 and a 200-day moving average of $2.27. Palisade Bio has a 12 month low of $0.75 and a 12 month high of $9.65. The firm has a market capitalization of $2.35 million, a P/E ratio of -0.06 and a beta of 1.49.

Wall Street Analysts Forecast Growth

Separately, Brookline Capital Management assumed coverage on shares of Palisade Bio in a research report on Wednesday, November 20th. They issued a “buy” rating and a $38.00 price objective for the company.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.